-
1.发明授权公开(公告)号：US08868350B2
公开(公告)日：2014-10-21
申请号：US13088044
申请日：2011-04-15
CPC分类号： A61M1/1603 , A61M1/16 , A61M1/1611 , A61M1/1613 , A61M1/1619 , A61M1/3609 , A61M2202/0498 , A61M2205/15 , A61M2205/3584 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2230/20 , G06F19/3481
摘要： A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.
-
2.发明申请THERAPY PREDICTION AND OPTIMIZATION FOR RENAL FAILURE BLOOD THERAPY, ESPECIALLY HOME HEMODIALYSIS 有权治疗失败血液治疗的治疗预防和优化，特别是家庭心脏病学公开(公告)号：US20120029324A1
公开(公告)日：2012-02-02
申请号：US13088064
申请日：2011-04-15
IPC分类号： A61B5/15
CPC分类号： A61M1/1603 , A61M1/16 , A61M1/1611 , A61M1/1613 , A61M1/1619 , A61M1/3609 , A61M2202/0498 , A61M2205/15 , A61M2205/3584 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2230/20 , G06F19/3481
摘要： A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.
摘要翻译： 在血液透析期间预测患者血清磷浓度的方法包括测量血液透析治疗会话时间的患者的血清磷浓度，以及通过初始血液透析期间患者的透析前和透析后体重之间的差异计算的超滤率 治疗时间除以治疗会话的总治疗时间，并估计患者的磷的移动清除率和磷酸盐的透析前分布体积。 然后可以在任何血液透析治疗期间的任何时间预测患者的血清磷浓度，其中估计磷移动清除率和患者的磷的透析前分布体积。
-
3.发明授权Therapy prediction and optimization for renal failure blood therapy, especially home hemodialysis 有权肾衰竭血液治疗的治疗预测和优化，特别是家庭血液透析公开(公告)号：US08845570B2
公开(公告)日：2014-09-30
申请号：US13088064
申请日：2011-04-15
CPC分类号： A61M1/1603 , A61M1/16 , A61M1/1611 , A61M1/1613 , A61M1/1619 , A61M1/3609 , A61M2202/0498 , A61M2205/15 , A61M2205/3584 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2230/20 , G06F19/3481
摘要： A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.
摘要翻译： 在血液透析期间预测患者血清磷浓度的方法包括测量血液透析治疗会话时间的患者的血清磷浓度，以及通过初始血液透析期间患者的透析前和透析后体重之间的差异计算的超滤率 治疗时间除以治疗会话的总治疗时间，并估计患者的磷的移动清除率和磷酸盐的透析前分布体积。 然后可以在任何血液透析治疗期间的任何时间预测患者的血清磷浓度，其中估计磷移动清除率和患者的磷的透析前分布体积。
-
4.发明申请THERAPY PREDICTION AND OPTIMIZATION FOR RENAL FAILURE BLOOD THERAPY, ESPECIALLY HOME HEMODIALYSIS 有权治疗失败血液治疗的治疗预防和优化，特别是家庭心脏病学公开(公告)号：US20110257891A1
公开(公告)日：2011-10-20
申请号：US13088044
申请日：2011-04-15
IPC分类号： G06F19/00
CPC分类号： A61M1/1603 , A61M1/16 , A61M1/1611 , A61M1/1613 , A61M1/1619 , A61M1/3609 , A61M2202/0498 , A61M2205/15 , A61M2205/3584 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2230/20 , G06F19/3481
摘要： A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.
摘要翻译： 在血液透析期间预测患者血清磷浓度的方法包括测量血液透析治疗会话时间的患者的血清磷浓度，以及通过初始血液透析期间患者的透析前和透析后体重之间的差异计算的超滤率 治疗时间除以治疗会话的总治疗时间，并估计患者的磷的移动清除率和磷酸盐的透析前分布体积。 然后可以在任何血液透析治疗期间的任何时间预测患者的血清磷浓度，其中估计磷移动清除率和患者的磷的透析前分布体积。
-
公开(公告)号：US08975240B2
公开(公告)日：2015-03-10
申请号：US13419701
申请日：2012-03-14
申请人： John Kenneth Leypoldt , Clifford J. Holmes , Sujatha Karoor , Catherine M. Hoff , Leo Martis , Rahul Tandon
发明人： John Kenneth Leypoldt , Clifford J. Holmes , Sujatha Karoor , Catherine M. Hoff , Leo Martis , Rahul Tandon
IPC分类号： A61K31/716 , A61K31/718 , C08L3/02 , A61K31/717
CPC分类号： A61K31/717 , A61K31/716 , A61K31/718 , C08L3/02
摘要： Peritoneal dialysis solutions including a glucose polymer and methods of using the dialysis solutions are disclosed herein. In a general embodiment, the peritoneal dialysis solution includes a glucose polymer in an amount to provide an increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed compared to conventional dialysis solutions containing icodextrin as the active pharmaceutical ingredient. The increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed is obtained by providing specific combinations of weight-average molecular weight, polydispersity index and concentration of the glucose polymer in the dialysis solution.
摘要翻译： 本文公开了包括葡萄糖聚合物的腹膜透析溶液和使用透析溶液的方法。 在一般实施方案中，腹膜透析溶液包含葡萄糖聚合物，其含量与给定量的碳水化合物相比提供了增加的超滤流体体积，与常规含有作为活性药物成分的伊曲诺白蛋白的透析溶液相比。 通过提供透析溶液中葡萄糖聚合物的重均分子量，多分散指数和浓度的特定组合，可以获得给定量的碳水化合物吸收增加的超滤液体积。
-
6.发明申请公开(公告)号：US20120238525A1
公开(公告)日：2012-09-20
申请号：US13419701
申请日：2012-03-14
申请人： John Kenneth Leypoldt , Clifford J. Holmes , Sujatha Karoor , Catherine M. Hoff , Leo Martis , Rahul Tandon
发明人： John Kenneth Leypoldt , Clifford J. Holmes , Sujatha Karoor , Catherine M. Hoff , Leo Martis , Rahul Tandon
IPC分类号： A61K31/715 , A61P13/12 , A61K31/718
CPC分类号： A61K31/717 , A61K31/716 , A61K31/718 , C08L3/02
摘要： Peritoneal dialysis solutions including a glucose polymer and methods of using the dialysis solutions are disclosed herein. In a general embodiment, the peritoneal dialysis solution includes a glucose polymer in an amount to provide an increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed compared to conventional dialysis solutions containing icodextrin as the active pharmaceutical ingredient. The increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed is obtained by providing specific combinations of weight-average molecular weight, polydispersity index and concentration of the glucose polymer in the dialysis solution.
摘要翻译： 本文公开了包括葡萄糖聚合物的腹膜透析溶液和使用透析溶液的方法。 在一般实施方案中，腹膜透析溶液包含葡萄糖聚合物，其含量与给定量的碳水化合物相比提供了增加的超滤流体体积，与常规含有作为活性药物成分的伊曲诺白蛋白的透析溶液相比。 通过提供透析溶液中葡萄糖聚合物的重均分子量，多分散指数和浓度的特定组合，可以获得给定量的碳水化合物吸收增加的超滤液体积。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.029 秒)
